Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as bicalutamide, may lessen the amount of androgens made by the body. Enzastaurin may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not
yet known whether giving bicalutamide together with enzastaurin is more effective than
bicalutamide alone in treating prostate cancer.
PURPOSE: This randomized phase II trial is studying bicalutamide to see how well it works
compared with giving bicalutamide together with enzastaurin in treating patients with
prostate cancer.